Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 3,094

Document Document Title
WO/2019/173806A1
A method of treating a cancer in a patient includes obtaining a sample from the patient, using a C-circle assay to detect a presence of an alternative lengthening of telomeres (ALT) phenotype in the sample, and administering an effect am...  
WO/2019/126253A8
Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmace...  
WO/2019/152946A1
Provided herein are compounds that are useful in the treatment of pain in a subject.  
WO/2019/121691A1
The present disclosure relates to compounds of Formula (I): (I) and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for...  
WO/2019/126253A1
Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmace...  
WO/2019/122129A1
The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds...  
WO/2019/126081A1
N-oxides, or salts thereof, wherein G, L2, R1, R5, R9, R10, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions...  
WO/2019/126113A1
Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, an...  
WO/2019/118799A1
Disclosed are compounds of Formula (I) (I) N-oxides, or salts thereof, wherein R1, G, A, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9...  
WO/2019/118528A1
Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemperal dementia (FTD).  
WO/2019/110521A1
The present invention relates to fluorophenyl substituted muscarinic receptor ligands with selectivity for M3 over M2 and to the use of these compounds in the treatment of various diseases such as asthma, chronic obstructive pulmonary di...  
WO/2019/105881A1
The invention relates to a novel and improved method for producing (3S)-3-(4-chlor-3-{[(2S,3R)-2-(4-chlorphenyl)-4,4,4-trifluor -3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid of the formula (I), to the compound of the formu...  
WO/2019/086434A1
The present invention discloses a process for the preparation of 2-benzhydryl-3-quinuclidinone (1). (I). The process of the invention allows to obtain the intermediate 2-benzhydryl-3-quinuclidinone (1) by reaction of 2-benzylidene-3-quin...  
WO/2019/015690A1
A deuterated 3-quinuclidone compound, a preparation method, and a use. In particular, the present invention provides a compound shown in general formula I or a pharmaceutically acceptable salt, isomer or a mixture thereof, solvate, polym...  
WO/2018/220501A1
The present invention relates to a process for the preparation of a novel and versatile synthesis intermediate and its use in the preparation of umeclidinium. The invention also relates to some reference standards allowing to detect impu...  
WO/2018/210229A1
Disclosed are a series of α-7 nicotine acetylcholine receptor agonists, and specifically disclosed are compounds of formula (I), pharmaceutically acceptable salts thereof or tautomers thereof, and pharmaceutical uses thereof.  
WO/2018/193463A1
The present invention discloses an improved process for preparation of substantially pure pentamethylene bis(1-(3,4-dimethoxybenzyl)-3,4-dihydro-6,7- dimethoxy-1H-isoquinoline-2-propionate), a compound of formula I and its acid addition ...  
WO/2018/163212A1
Provided herein is a process for the preparation of umeclidinium bromide and intermediates thereof, wherein pure form of umeclidinium bromide is achieved by a two step process under mild conditions.  
WO/2018/157277A1
The present invention provides a compound of Formula (I), where in X is selected from the group consisting of CH and N; Q is selected from the group consisting of CH3 and H; R is selected from the group consisting of (II) and (III), or a...  
WO/2018/150437A1
Provided herein is a process for synthesis of aclidinium bromide and intermediates thereof, wherein the process for the preparation of aclidinium bromide increases the % yield of aclidinium bromide by about 70% to 90%.  
WO/2018/152368A1
Provided is a compound of Formula (I), wherein the variable groups are defined herein.  
WO/2018/108089A1
Provided are a class of compounds, as represented by formula (I), having a bifunctional active quaternary ammonium salt structure of a β2 adrenoreceptor agonist and an M receptor antagonist, a pharmaceutically acceptable salt, solvate, ...  
WO/2018/087561A1
The present invention discloses processes comprising a) reacting ethyl isonipecotate with 1 -bromo-2- chloroethane in the presence of an organic base in a solvent to form ethyl 1 -(2-chloroethyl)piperidine- 4-carboxylate (II) or a salt t...  
WO/2018/011611A1
The object of the invention relates to the salts of encenicline formed with inorganic and organic acids of general formula (I), as well as to the use of these for the production of pharmaceutical preparations primarily suitable for the t...  
WO/2018/011227A1
The invention relates to a compound of Formula I : Formula I, or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of tryptophan 2...  
WO/2017/218920A1
This invention is directed to asymmetric synthesis of funapide, which is useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.  
WO/2017/200184A1
The present invention relates to a novel chiral phase-transfer catalyst, and a method for preparing an α-amino acid by using the same. According to the present invention, an α-amino acid could be chirally synthesized in a high yield un...  
WO/2017/178897A3
Methods of treating and preventing conditions of a nasal or paranasal mucous membrane are described. The methods include administering a pharmaceutical composition including a nicotinic acetylcholine receptor (nAChR) agonist, such as (S)...  
WO/2017/176948A1
This invention relates to processes for the preparation of antiparasitic isoxazoline compounds enriched in an enantiomer using quinine- based chiral phase transfer catalysts. The invention also relates to novel quinine-based phase transf...  
WO/2017/148455A1
The invention relates to iodinated aromatic choline analogs of general formula wherein at least one R is iodine; the quaternary ammonium group comprises a hydroxyl substituent, and further substituent are as defined in the claims. The co...  
WO/2017/120532A1
Provided is a phosphate salt of quinuclidin-4-ylmethyl 4-methyl-1H-indole-3- carboxylate, in particular polymorphic Form A, a process for their preparation of said salt, in particular in polymorphic Form A, and a pharmaceutical compositi...  
WO/2017/083242A1
Compounds capable of inhibiting suppression of tumorgenicity 2 (ST2) are disclosed. The compounds are useful in the treatment of a variety of diseases and conditions, such as alleviation of graft-versus-host disease (GVHD), cardiovascula...  
WO/2017/075694A1
The present invention relates to compounds of formula (I) wherein G1 to G8 are as defined herein. The compounds are PK inhibitors and as such represent a new approach to treating pathogenic infections, including multidrug resistant patho...  
WO/2017/069226A1
A compound represented by general formula [I] (in the formula, X represents N or the like, Y represents CH or the like, RA represents an optionally substituted cycloalkyl group or the like, R1 represents an alkyl group or the like, R2 re...  
WO/2017/060287A1
The present invention relates to a process for the preparation of an amide from a carboxylic acid chloride and an organic molecule comprising both a primary amine group and a tertiary amine group, wherein the nitrogen atom of the tertiar...  
WO/2017/060290A1
The present invention relates to a crystalline forms of encenicline hydrochloride and a process for their preparation. The invention also concerns a pharmaceutical compositions comprising an effective amount of the crystalline form of en...  
WO/2017/051761A1
The prodrug or a salt thereof according to the present invention is represented by the formula: D-X-L. (In the formula, D represents a useful compound and becomes D-X-H. X represents NR1, O, S, or Se. R1 represents a hydrogen atom, a sub...  
WO/2017/023700A1
Disclosed herein are compositions which include nicotinic receptor agonists, specifically of the α4β2 or α7 nAChR subtypes, and methods for treating or suppressing cough.  
WO/2015/185649A9
The invention relates to novel compounds which are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof. M...  
WO/2016/203112A1
The present invention provides novel spiro[cyclobutane-1,3'-indolin]-2'- derivatives of formula (I) in which Cy R1, R2, R4, L and 'm' are have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The com...  
WO/2016/201096A1
The present invention relates to novel aminobenzisoxazole compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of ot7-nAChR, and methods of preparing these compounds and compositions, ...  
WO/2016/193241A1
The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations w...  
WO/2016/193240A1
The invention relates to novel compounds which are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.  
WO/2016/162878A1
The present invention discloses the process for preparation of 1- ¬Azoniabicyclo[2.2.2]octane,3-[(hydroxydi-2-thienylacety1)o xy]-1-(3¬iphenoxypropy1)-, bromide, (3R)- and its novel crystalline form-I  
WO/2016/156836A1
A process for preparing (3R)-3-[2-Hydroxy(di-2-thienyl)acetoxy]-1-(3-phenoxypropyl)- 1- azoniabicyclo[2.2.2]octane bromide (aclidinium bromide) comprises reacting 2-hydroxy-2,2- dithien-2-ylacetic acid 1-azabicyclo[2.2.2]oct-3(R) yl meth...  
WO/2016/159268A1
Provided is a novel non-deliquescent acid addition salt of 3-aminoquinuclidine, which is a compound industrially useful as an intermediate for a medicine and the like. An acid addition salt of 3-aminoquinuclidine selected from the group ...  
WO/2016/140136A1
Provided is a new agent for treating chronic obstructive pulmonary disease. The present invention provides quinuclidine derivatives represented by general formula (1), and a pharmaceutical containing the same. (In the formula, R1 indicat...  
WO/2016/131789A1
The present invention relates to benzopyrrolidone derivatives and/or pharmaceutically acceptable salts thereof for the use in the treatment of infectious diseases or cancer, and pharmaceutical compositions containing at least one of said...  
WO/2016/128456A1
The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations w...  
WO/2016/124125A1
The present invention relates to a new crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxa mide hydrochloride and a preparation method for the new crystalline form. The crystalline form has advantageous prope...  

Matches 1 - 50 out of 3,094